scholarly journals Boron neutron capture therapy in cancer: past, present and future

2007 ◽  
Vol 51 (5) ◽  
pp. 852-856 ◽  
Author(s):  
Mario A. Pisarev ◽  
Maria Alejandra Dagrosa ◽  
Guilermo J. Juvenal

Undifferentiated thyroid cancer (UTC) is a very aggressive tumor with no effective treatment, since it lacks iodine uptake and does not respond to radio or chemotherapy. The prognosis of these patients is bad, due to the rapid growth of the tumor and the early development of metastasis. Boron neutron capture therapy (BNCT) is based on the selective uptake of certain boron non-radioactive compounds by a tumor, and the subsequent irradiation of the area with an appropriate neutron beam. 10B is then activated to 11B, which will immediately decay releasing alpha particles and 7Li, of high linear energy transfer (LET) and limited reach. Clinical trials are being performed in patients with glioblastoma multiforme and melanoma. We have explored its possible application to UTC. Our results demonstrated that a cell line of human UTC has a selective uptake of borophenylalanine (BPA) both in vitro and after transplantation to nude mice. Treatment of mice by BNCT led to a complete control of growth and cure of 100% of the animals. Moreover dogs with spontaneous UTC also have a selective uptake of BPA. At the present we are studying the biodistribution of BPA in patients with UTC before its application in humans.

2018 ◽  
Author(s):  
Guillaume Vares ◽  
Vincent Jallet ◽  
Yoshitaka Matsumoto ◽  
Cedric Rentier ◽  
Kentaro Takayama ◽  
...  

AbstractTreatment resistance, relapse and metastasis remain critical issues in some challenging cancers, such as chondrosarcomas. Boron-neutron Capture Therapy (BNCT) is a targeted radiation therapy modality that relies on the ability of boron atoms to capture low energy neutrons, yielding high linear energy transfer alpha particles. We have developed an innovative boron-delivery system for BNCT, composed of multifunctional fluorescent mesoporous silica nanoparticles (B-MSNs), grafted with an activatable cell penetrating peptide (ACPP) for improved penetration in tumors and with Gadolinium for magnetic resonance imaging (MRI)in vivo. Chondrosarcoma cells were exposedin vitroto an epithermal neutron beam after B-MSNs administration. BNCT beam exposure successfully induced DNA damage and cell death, including in radio-resistant ALDH+ cancer stem cells (CSCs), suggesting that BNCT using this system might be a suitable treatment modality for chondrosarcoma or other hard-to-treat cancers.


Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1551 ◽  
Author(s):  
Koji Takeuchi ◽  
Yoshihide Hattori ◽  
Shinji Kawabata ◽  
Gen Futamura ◽  
Ryo Hiramatsu ◽  
...  

Boron neutron capture therapy (BNCT) is a form of tumor-cell selective particle irradiation using low-energy neutron irradiation of boron-10 (10B) to produce high-linear energy transfer (LET) alpha particles and recoiling 7Li nuclei (10B [n, alpha] 7Li) in tumor cells. Therefore, it is important to achieve the selective delivery of large amounts of 10B to tumor cells, with only small amounts of 10B to normal tissues. To develop practical materials utilizing 10B carriers, we designed and synthesized novel dodecaboranethiol (BSH)-containing kojic acid (KA-BSH). In the present study, we evaluated the effects of this novel 10B carrier on cytotoxicity, 10B concentrations in F98 rat glioma cells, and micro-distribution of KA-BSH in vitro. Furthermore, biodistribution studies were performed in a rat brain tumor model. The tumor boron concentrations showed the highest concentrations at 1 h after the termination of administration. Based on these results, neutron irradiation was evaluated at the Kyoto University Research Reactor Institute (KURRI) with KA-BSH. Median survival times (MSTs) of untreated and irradiated control rats were 29.5 and 30.5 days, respectively, while animals that received KA-BSH, followed by neutron irradiation, had an MST of 36.0 days (p = 0.0027, 0.0053). Based on these findings, further studies are warranted in using KA-BSH as a new B compound for malignant glioma.


2009 ◽  
Vol 14 (6) ◽  
pp. 883-890 ◽  
Author(s):  
Antonella Crivello ◽  
Carlo Nervi ◽  
Roberto Gobetto ◽  
Simonetta Geninatti Crich ◽  
Iboya Szabo ◽  
...  

2007 ◽  
Vol 69 (4) ◽  
pp. 1059-1066 ◽  
Author(s):  
Maria Alejandra Dagrosa ◽  
Lisa Thomasz ◽  
Juan Longhino ◽  
Marina Perona ◽  
Osvaldo Calzetta ◽  
...  

2016 ◽  
Vol 1 (2) ◽  
pp. 108
Author(s):  
Widarto Widarto ◽  
Isman Mulyadi Tri Atmoko ◽  
Gede Sutresna Wijaya

The quality manajement system program of in vitro / in vivo test facility of  Boron Neutron Capture Therapy (BNCT) methode as quality assurance requirement for utilization of radial pearcing beamport of Kartini research have been done.  Identification and management of technical specification and parameters meassurement of to the radial piercing beamport have been determined for preparing in vitro / in vivo test facility. The parameters are epithermal neutron flux is  9,8243E+05  n cm<sup>-2</sup> s<sup>-1</sup>and  thermal neutron flux is 3,0691E+06 n cm<sup>-2</sup> s<sup>-1</sup>, radiation shielding of parafin,  dimension and size  of piercing radial and instrumentatin and control system for automatic transfer of in vitro / in vivo samplels have been documented. Management system of the documents for fullfil  basic guidance to perform working job of in vitro / in vivo at the piercing radial beamport of Kartini Research Reactor in order purpose utilization of the reactor  for safety worker of the radiation area, society  and invironment beeing safely


Oncotarget ◽  
2017 ◽  
Vol 8 (22) ◽  
pp. 36614-36627 ◽  
Author(s):  
Weirong Kang ◽  
Darren Svirskis ◽  
Vijayalekshmi Sarojini ◽  
Ailsa L. McGregor ◽  
Joseph Bevitt ◽  
...  

2013 ◽  
Vol 257 (15-16) ◽  
pp. 2213-2231 ◽  
Author(s):  
Daniela Pietrangeli ◽  
Angela Rosa ◽  
Sandra Ristori ◽  
Anna Salvati ◽  
Saverio Altieri ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document